alexa Anti-mycobacterial Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Anti-mycobacterial Therapy

Tuberculosis (TB) remains the global problem of mankind with 8.8 million new cases of TB diagnosed each year and 1.4 million people dying from the disease. The emergence of Multi-Drug- Resistant (MDR) and extensively drug-resistant TB threatens disease control efforts throughout the world. About 50 million people are estimated to be infected with resistant strains of Mycobacterium tuberculosis. In the last decade the Ukraine experienced marked increase in the proportion of TB strains resistant to one or more anti-mycobacterial drugs, causing reduced effectiveness of standard chemotherapy. As a result the frequency of Relapsed or Recurrent Pulmonary Tuberculosis (RPTB) becomes higher. The success of treating relapsed tuberculosis remains low resulting in higher rate of transition to chronic disease and increased mortality. One of reasons for relapse include disorders in oxidant-antioxidant system, which affect the proper immune surveillance and exaggerates destructive inflammatory process underlying the variety of pathological changes. Several studies have implicated local and systemic intensification of prooxidant- antioxidant system in various forms of pulmonary tuberculosis.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top